Abeona Therapeutics Details Pathway for Advancing Lead Clinical Programs

Abeona Therapeutics (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced key pipeline updates during the Company’s 2018 R&D Day.

As quoted in the press release:

“The important clinical and preclinical updates we shared today further establish Abeona’s pathway to bring long-term value to our shareholders and hope to our patients,” said João Siffert, M.D., interim Chief Executive Officer, Chief Medical Officer and Head of R&D. “We are very pleased to share next steps for our lead programs and to unveil the potential of the novel AIMTMAAV vector platform that could be a catalyst for the next generation of gene therapy.”

Click here to read the full press release.

Is it a good time to buy gold stocks?

Learn to profit from gold’s low price this year!

The post Abeona Therapeutics Details Pathway for Advancing Lead Clinical Programs appeared first on Investing News Network.

Investing News Network

, , , , , , ,

Comments are closed.